United Kingdom (UK)
Recombinant monoclonal antibody to PD-1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Anti-human PD-1 antibody.
UniProt Accession Number of Target Protein: Q15116
Alternative Name(s) of Target: CD279; Programmed cell death protein 1; PDCD1; PD-1; hPD-1; Human programmed cell death receptor-1
Immunogen: The original antibody was generated by immunizing transgenic mice with PD-1.
Specificity: The antibody is specific for PD-1. The antibody binds the extracellular region of the human PD-1 protein receptor. PD-1 is a type I membrane protein with 288 amino acids, and is one of the main known immune checkpoints. PD-1 is expressed in activated T lymphocytes, and it binds ligands PD-L1 and PD-L2.
Application Notes: The specificity of the original format of the antibody was confirmed by ELISA analysis (EC50 = 76 pM). The antibody blocked the binding between PD-1 protein and its ligands PD-L1 and PD-L2 by the receptor ligand binding assay of PD-1 protein. Lymphocyte stimulation assay detected that PD-1 antibody blocked the binding of PD-1 protein to its ligands PD-L1 and PD-L2, thereby releasing its inhibition of T lymphocyte activity (CN106928361A).
Antibody first published in: PMID: